Opportunities for Pharmacotherapy at the Intersection of Metabolic Syndrome and Hemostasis

Title: Opportunities for Pharmacotherapy at the Intersection of Metabolic Syndrome and Hemostasis

Volume: 12 Issue: 9

Author(s): Laura F. Michael, Veena Rao, Patrick McCollam, Mark C. Kowala and John Wetterau

Affiliation:

Keywords: Metabolic syndrome, hemostatis, thrombosis, coagulation, cardiovascular disease, diabetes, cardio-metabolic abnormalities, metabolic syndrome patients, thromboembolic events, cardiovascular risk, coronary atheroma progression, Elevated triglyceride-rich VLDL, adipocyte dysfunction, coronary heart disease (CHD)

Abstract: Hemostatic balance is regulated by many factors that may become perturbed by cardio-metabolic abnormalities. Indeed, patients with multiple components of the metabolic syndrome have increased risk of atherosclerosis, hemostatic disorders and thrombotic events. This review focuses on the interrelationship between the metabolic syndrome components and thrombotic and thromboembolic events, the potential underlying mechanisms that lead to metabolic and hemostatic disorders in metabolic syndrome patients, the existing therapeutics aimed at reducing major cardiovascular events, and new therapeutic approaches to address pro-coagulant states.

Cite this article as:

F. Michael Laura, Rao Veena, McCollam Patrick, C. Kowala Mark and Wetterau John, Opportunities for Pharmacotherapy at the Intersection of Metabolic Syndrome and Hemostasis, Current Pharmaceutical Biotechnology 2011; 12 (9) . https://dx.doi.org/10.2174/138920111798281081